Nigeria

Reimbursed Care Access

Nigeria maintains a highly restrictive national drug control regime: classical psychedelics and novel psychoactive tryptamines/phenethylamines are effectively prohibited for general use and only accessible in tightly controlled research settings. Medical and legally reimbursed access is limited to established medicines (e.g., ketamine as an anaesthetic), which are prescription-only and regulated by NAFDAC; there is no evidence of marketed esketamine (Spravato) registration or public reimbursement for psychedelic-assisted psychiatric care. Enforcement and criminal penalties for possession, trafficking or unauthorised use of psychotropic substances are severe under the NDLEA framework.